KUALA LUMPUR (Oct 5): The Malaysian healthcare sector in particular is vulnerable to global supply chain disruptions and inflationary pressures, posing a potential downside to the group’s performance moving forward, said TMC Life Sciences Bhd chairman Datuk Sri Mohd Mokhtar Mohd Shariff.

In his statement to shareholders in the company's 2022 Annual Report released on Wednesday (Oct 5), Mohd Mokhtar said that as part of efforts to further improve governance and risk management frameworks within TMC Life Sciences, the group has embarked on a review of its Environmental, Social and Governance ("ESG") strategic roadmap.

“We will focus on increasing accessibility to our services by expanding the depth and breadth of our services, while holding ourselves accountable to provide the highest level of medical care and patient safety.

“Through research, education and innovation, we will continue to focus on providing value-based care to our patients through various platforms and channels, including digital health,” he said.

Mohd Mokhtar said TMC Life Sciences fully believes in its vision to help people lead healthier lives by making healthcare accessible, accountable and sustainable.

“By building a comprehensive and inclusive health service ecosystem and achieving international best practice and standards of care, the group aims to deliver sustainable value to all its stakeholders,” he said.

At the time of writing, TMC Life share price was unchanged at 58.5 sen, with 168,100 shares done.